Morepen Laboratories Ltd

- No immediate plans for new fundraising through equity or debt as the company currently has sufficient cash flows. - Past preferential allotment was postponed to seek higher prices; discussions with investors are ongoing but no final decisions made. - The company is open to taking term loans for buildings or other needs if required but has not yet signed any agreements. - CAPEX for the current year (around Rs.35-40 crores) and investments in Medical Devices (around Rs.20 crores) will be funded through internal accruals. - Working capital requirements are increasing, and the company may consider local arrangements for working capital financing if needed. - Management is keen on wealth creation for all shareholders and cautious about undervaluation in any fundraising.

- Total CAPEX requirement is Rs.178 crores over three years; Rs.35-40 crores expected to be spent in the current year. - API segment investment of Rs.35-40 crores planned from internal accruals. - Medical Devices segment to receive around Rs.20 crores investment, also from internal accruals. - Potential backward integration for intermediate chemicals currently imported from China. - Additional investment may be needed for new API plant building and machinery; higher CAPEX expected next financial year. - Open to term loans if required for buildings or working capital but currently relying on internal accruals. - No major investments planned yet for Sputnik vaccine bulk production; only working capital might be needed. - Strategic focus on biosimilars and new biological products with expansions aligning to these areas.

- The company achieved a 50% revenue growth in Q1 FY22, a phenomenal increase from previous quarters. - Dr. Morepen portfolio is expected to grow to around Rs.1,000 crores in the next two years, indicating strong growth in OTC and medical devices. - Diagnostics division sales grew 189% this quarter, with an increasing share of the company’s revenue; the division is expected to remain a key growth driver. - API business growth is steady at 17% with plans to focus on new molecules and products linked to a $40 billion market with expiring patents. - Medical Devices segment expanding capacity and adding new products, projected to keep growing along with Finished Dosage business recovery (30% growth). - COVID-driven demand for diagnostic devices may normalize but heightened health awareness is expected to sustain higher usage and sales long-term. - Overall company poised for continued robust growth fueled by expansion in diagnostics, formulations, and new product launches.

- Q1 FY22 showed a remarkable 50% revenue growth and 63% EBITDA increase, signaling strong momentum. - Profit before tax increased by 97%, profit after tax by 57%, and EPS is Rs.0.68 for the quarter, annualized to around Rs.2.40. - EBITDA margins improved from 10.8% to 11.7%, expected to inch more positive with stable margins across segments. - API segment growth driven by new molecule capacity and ANDA filings targeting a $40 billion market over next two years. - Dr. Morepen OTC portfolio expected to grow to Rs.1,000 crores in next 1-2 years, potentially leading to separate subsidiary and IPO. - Medical Devices segment demonstrating strong growth and capacity expansion, supported by COVID-driven demand. - CAPEX of Rs.35-40 crores planned this year to support expansion, mainly via internal accruals, with potential term loans as needed. - Overall outlook remains positive with management confident of sustained growth and profitability improvements.

- The transcript does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited. - For the Sputnik vaccine, six trial batches have been sent for testing, with commercial production expected to start within 4-6 weeks pending approval. - The company has a capacity to fill up to 250 million doses per annum for Sputnik, potentially increasing to 500 million doses based on bulk supply and demand. - Discussions on capacity expansion in API and Medical Devices suggest growing demand and internal accrual investments, but no specific order backlog figures are provided. - The company’s diagnostic devices division sales have grown significantly, indicating strong demand, but no order book details are disclosed. No direct information on a specific order book or pending orders is available in the transcript.